Duyuru • 23h
Royalty Pharma plc Announces Appointment of Greg Raskin as Senior Vice President, Head of Academic Initiatives, Effective August 2026 Royalty Pharma plc announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. Greg will lead Royalty Pharma's outreach efforts with academic and non-profit institutions as well as oversee the Royalty Pharma Translational Prize. Greg joined Royalty Pharma after nearly three decades at the intersection of science, medicine and investing, and most recently served as Senior Vice President, Technology Development at Memorial Sloan Kettering Cancer Center. Prior to joining Royalty Pharma, Greg spent more than a decade at Memorial Sloan Kettering Cancer Center, most recently as Senior Vice President, Technology Development, where he led biotechnology startup efforts, technology transfer, monetization and business development. Earlier in his career, Greg was a Vice President at AllianceBernstein, where he led healthcare and life sciences investing for the firm’s venture capital fund. Previously, he served as a biotech analyst at Baker Brothers Investments and as a management consultant at McKinsey & Company, where he primarily worked with pharmaceutical and biotech companies. Greg received his M.D. from Yale School of Medicine and a B.A. in molecular biophysics and biochemistry from Yale College. He currently serves as a Lecturer in the Department of Economics at both Stanford University and Yale University, where he teaches courses on the economics and science of drug development. Declared Dividend • Jul 22
First quarter dividend of US$0.23 announced Shareholders will receive a dividend of US$0.23. Ex-date: 14th August 2026 Payment date: 10th September 2026 Dividend yield will be 1.2%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (47% earnings payout ratio) but not covered by cash flows (117% cash payout ratio). The dividend has increased by an average of 7.8% per year over the past 6 years and payments have been stable during that time. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Jul 18
Royalty Pharma plc Declares Third Quarter 2026 Dividend, Payable on September 10, 2026 The board of directors of Royalty Pharma plc has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026. Duyuru • Jul 16
Royalty Pharma plc to Report Q2, 2026 Results on Aug 05, 2026 Royalty Pharma plc announced that they will report Q2, 2026 results Pre-Market on Aug 05, 2026 Duyuru • Jun 10
Royalty Pharma plc Announces Resignation of Errol Bento Jose Trinidade De Souza as Director, Effective June 4, 2026 Royalty Pharma Plc announced the resignation of Errol Bento Jose Trinidade De Souza as director of the company, with effect from June 4, 2026. Duyuru • Apr 17
Royalty Pharma plc Declares Dividend for the Second Quarter 2026, Payable on June 10, 2026 Royalty Pharma plc approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026. Duyuru • Apr 16
Royalty Pharma plc to Report Q1, 2026 Results on May 06, 2026 Royalty Pharma plc announced that they will report Q1, 2026 results Pre-Market on May 06, 2026 Duyuru • Apr 13
Royalty Pharma plc, Annual General Meeting, Jun 04, 2026 Royalty Pharma plc, Annual General Meeting, Jun 04, 2026. Location: 110 east 59th street, ny 10022, new york United States Duyuru • Mar 23
Royalty Pharma plc Appoints Lucas Glass as Head of Artificial Intelligence, Effective April 2026 Royalty Pharma plc announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma. Lucas most recently served as Senior Vice President of Technology at IQVIA, a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, where he led enterprise architecture, domain architecture and platform engineering initiatives. Earlier in his career, Lucas held data science and statistical leadership roles at Routine Recovery and the U.S. Department of Justice. Lucas completed doctoral studies in statistics at Temple University, an MS in biostatistics from Drexel University and a BA in physics from Boston University. Duyuru • Mar 18
Royalty Pharma plc Announces Executive Appointments Royalty Pharma plc announced that Greg Butz will join Royalty Pharma as Executive Vice President, Partnering & Investments, effective June 2026. Greg joins Royalty Pharma from Bank of America, where he was the Global Co-Head of Healthcare Investment Banking. At Bank of America, Greg worked with public and private biopharma companies across a range of capital raising and strategic advisory transactions. Prior to his acting as Global Co-Head of Healthcare, Greg held Co-Head North American Healthcare Investment Banking and Head of Life Sciences Investment Banking roles at Bank of America. Greg graduated with a BA from Williams College and received an MBA from Dartmouth. In connection with hiring Mr. Butz, Chris Hite has been appointed Chairman, Partnering & Investments where he will continue to expand Royalty Pharma’s global relationship network and play a central role in transactions. Chris is a highly valued partner whose leadership, insight, and dedication have been instrumental to the growth and evolution of Royalty Pharma, as well as to the advancement of the broader royalty market. The company announced recent expansion of its leadership team, including the addition of Ken Sun as new Head of Asia. Together, Greg and Ken working with Chris Hite will be highly complementary and will enhance ability to originate and execute differentiated royalty transactions worldwide. Duyuru • Mar 03
Royalty Pharma plc Appoints Kenneth Sun as Senior Vice President and Head of Asia, Effective May 2026 Royalty Pharma plc announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company’s royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking. Asia-based biotechnology companies are now prolific creators of innovative therapeutics. In 2025, the out-licensing of Chinese medicines alone comprised over $130 billion of announced transaction value, up from approximately $14 billion in 2021, as multinational pharmaceutical companies increasingly recognized the value of this innovation. This momentum is expected to continue into 2026 and beyond, as modalities, therapeutic areas and deal structures out of Asia become increasingly innovative, comprehensive and diverse. The royalties from these transactions are creating a new market opportunity for royalty-based funding. Royalty Pharma will partner with biotechnology innovators to build the royalty market in greater Asia, just as Royalty Pharma played a foundational role in establishing the biopharma royalty market in the west by working closely with universities, research institutions and biopharma companies over two decades ago. In his previous role as Managing Director, Head of Asia Pacific Healthcare Investment Banking at Morgan Stanley, Ken led the establishment of the bank’s leadership position in China. He advised a diverse spectrum of strategic clients, including biotech, medtech, CRO, pharmaceutical and healthcare service companies. Ken successfully led origination and execution of notable and industry defining healthcare transactions across IPOs, M&A, and biotech licensing advisory, with a primary focus on Greater China. He brings more than 18 years of investment banking experience, having previously worked at China Renaissance and BNP Paribas. Ken holds a Bachelor’s degree in Electrical Engineering from Queen’s University, Canada. Recent Insider Transactions • Feb 21
Insider recently sold Mex$2.0b worth of stock On the 18th of February, Mario Giuliani sold around 3m shares on-market at roughly Mex$722 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of Mex$5.1b more than they bought in the last 12 months. Reported Earnings • Feb 12
Full year 2025 earnings released: EPS: US$1.37 (vs US$1.92 in FY 2024) Full year 2025 results: EPS: US$1.37 (down from US$1.92 in FY 2024). Revenue: US$2.38b (up 5.1% from FY 2024). Net income: US$771.0m (down 10% from FY 2024). Profit margin: 32% (down from 38% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Global Pharmaceuticals industry. Duyuru • Feb 11
Royalty Pharma plc Provides Earnings Guidance for the Full Year 2026 Royalty Pharma plc provided earnings guidance for the full year 2026. For the period, the company expects 2026 Portfolio Receipts to be between $3,275 million and $3,425 million. Portfolio Receipts guidance represents expected growth of 14% to 16% in 2025. Royalty Pharma’s full year 2025 guidance reflects a negligible estimated foreign exchange impact to Portfolio Receipts, assuming current foreign exchange rates prevail for the rest of 2025. Declared Dividend • Feb 05
Third quarter dividend of US$0.23 announced Shareholders will receive a dividend of US$0.23. Ex-date: 20th February 2026 Payment date: 10th March 2026 Dividend yield will be 1.8%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (49% earnings payout ratio) and cash flows (57% cash payout ratio). The dividend has increased by an average of 9.4% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 24% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Jan 21
Royalty Pharma plc to Report Q4, 2025 Results on Feb 11, 2026 Royalty Pharma plc announced that they will report Q4, 2025 results Pre-Market on Feb 11, 2026 Declared Dividend • Jan 19
Third quarter dividend of US$0.23 announced Shareholders will receive a dividend of US$0.23. Ex-date: 20th February 2026 Payment date: 10th March 2026 Dividend yield will be 1.8%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (49% earnings payout ratio) and cash flows (57% cash payout ratio). The dividend has increased by an average of 9.4% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 24% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Jan 09
Royalty Pharma plc Declares Dividend on Class A Ordinary Share for the First Quarter of 2026, Payable on March 10, 2026 Royalty Pharma plc announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 20, 2026. Reported Earnings • Nov 07
Third quarter 2025 earnings released: EPS: US$0.67 (vs US$1.22 in 3Q 2024) Third quarter 2025 results: EPS: US$0.67 (down from US$1.22 in 3Q 2024). Revenue: US$609.3m (up 7.9% from 3Q 2024). Net income: US$288.2m (down 47% from 3Q 2024). Profit margin: 47% (down from 96% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Global Pharmaceuticals industry. Duyuru • Nov 06
Royalty Pharma plc Announces Earnings Guidance for the Full Year 2025 Royalty Pharma plc announced earnings guidance for the full year 2025. For the period, the company expects 2025 Portfolio Receipts to be between $3,200 million and $3,250 million (previously $3,050 million to $3,150 million), representing expected growth of 14% to 16% (previously 9% to 12%). New Risk • Nov 05
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 2.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 2.3% per year for the foreseeable future. Minor Risk High level of debt (77% net debt to equity). Declared Dividend • Nov 04
Second quarter dividend of US$0.22 announced Shareholders will receive a dividend of US$0.22. Ex-date: 14th November 2025 Payment date: 10th December 2025 Dividend yield will be 1.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (37% earnings payout ratio) and cash flows (72% cash payout ratio). The dividend has increased by an average of 8.0% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 21% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Declared Dividend • Oct 27
Second quarter dividend of US$0.22 announced Shareholders will receive a dividend of US$0.22. Ex-date: 14th November 2025 Payment date: 10th December 2025 Dividend yield will be 2.0%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (37% earnings payout ratio) and cash flows (72% cash payout ratio). The dividend has increased by an average of 8.0% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 9.4% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Oct 17
Royalty Pharma plc Approves Dividend on Class A Ordinary Share for Fourth Quarter of 2025 , Payable on December 10, 2025 The board of directors of Royalty Pharma plc approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on December 10, 2025, to shareholders of record at the close of business on November 14, 2025. Duyuru • Oct 02
Royalty Pharma plc to Report Q3, 2025 Results on Nov 05, 2025 Royalty Pharma plc announced that they will report Q3, 2025 results Pre-Market on Nov 05, 2025 Duyuru • Sep 30
Royalty Pharma plc Appoints Ted W. Love as Lead Independent Director Royalty Pharma plc announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. About Ted W. Love, MD: Dr. Love serves as BIO’s Immediate Past Chair of its Board of Directors following a two-year term as Chairman (2023-2025). Previously, he served as President and CEO of Global Blood Therapeutics (GBT) as well as a member of its board. Before GBT, he was EVP, Research and Development and Technical Operations, at Onyx Pharmaceuticals. Prior to Onyx, Ted served as President, CEO and Chairman of Nuvelo. Earlier in his career, Ted served as SVP, Development, at Theravance and held a number of senior management positions in medical affairs and product development at Genentech, including as Chairman of Genentech’s Product Development Committee and VP, Product Development. Dr. Love serves on the Board of Directors of Gilead Sciences and Structure Therapeutics. Ted holds an MD from Yale Medical School and a BA in molecular biology from Haverford College. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital. Duyuru • Aug 14
Royalty Pharma plc Announces Stepdown of Henry Fernandez as Its Lead Independent Director, Effective August 13, 2025 Royalty Pharma plc announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021. The company intends to name a new Lead Independent Director in the near future. Duyuru • Jul 18
Royalty Pharma plc Declares Dividend on Class A Ordinary Share for Third Quarter of 2025, Payable on September 10, 2025 The board of directors of Royalty Pharma plc has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. Board Change • Jul 10
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 1 highly experienced director. Director Vlad Coric was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jul 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 1 highly experienced director. Director Vlad Coric was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Apr 22
Royalty Pharma plc Declares Second Quarter 2025 Dividend on A Ordinary Share, Payable on June 10, 2025 The board of directors of Royalty Pharma plc has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. Duyuru • Apr 18
Royalty Pharma plc to Report Q1, 2025 Results on May 08, 2025 Royalty Pharma plc announced that they will report Q1, 2025 results Pre-Market on May 08, 2025 Duyuru • Apr 14
Royalty Pharma plc, Annual General Meeting, May 12, 2025 Royalty Pharma plc, Annual General Meeting, May 12, 2025. Location: 110 east 59th street, new york 10022, new york United States Duyuru • Apr 09
Royalty Pharma plc Appoints Vlad Coric, M.D. to Its Board of Directors Royalty Pharma plc announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug candidate, zavegepant, as the first intranasal CGRP antagonist for ultra-rapid relief of migraine. During his tenure, Dr. Coric oversaw Biohaven’s impressive growth from its founding through its sale to Pfizer in May of 2022 for approximately $13 billion in total consideration.Dr. Coric has more than 20 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb prior to leading Biohaven. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neurology, psychiatry, immunology, virology, oncology and immuno-oncology. During his career, he has been involved in multiple drug development programs. Dr. Coric completed his postdoctoral internship, residency and fellowship at Yale School of Medicine, earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree. Upcoming Dividend • Feb 14
Upcoming dividend of US$0.22 per share Eligible shareholders must have bought the stock before 21 February 2025. Payment date: 10 March 2025. Payout ratio is a comfortable 44% but the company is paying out more than the cash it is generating. Trailing yield: 2.7%. Lower than top quartile of Mexican dividend payers (6.2%). Higher than average of industry peers (2.4%). Reported Earnings • Feb 11
Full year 2024 earnings released: EPS: US$1.93 (vs US$2.54 in FY 2023) Full year 2024 results: EPS: US$1.93 (down from US$2.54 in FY 2023). Revenue: US$2.26b (down 3.9% from FY 2023). Net income: US$859.0m (down 24% from FY 2023). Profit margin: 38% (down from 48% in FY 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Global Pharmaceuticals industry. Duyuru • Jan 29
Royalty Pharma plc to Report Q4, 2024 Results on Feb 11, 2025 Royalty Pharma plc announced that they will report Q4, 2024 results Pre-Market on Feb 11, 2025 Declared Dividend • Jan 20
Third quarter dividend of US$0.22 announced Shareholders will receive a dividend of US$0.22. Ex-date: 21st February 2025 Payment date: 10th March 2025 Dividend yield will be 1.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (32% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 8.8% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 9.2% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Valuation Update With 7 Day Price Move • Jan 16
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to Mex$631, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 13x in the Pharmaceuticals industry globally. Total loss to shareholders of 19% over the past three years. Duyuru • Jan 13
Royalty Pharma plc (NasdaqGS:RPRX) announces an Equity Buyback for $3,000 million worth of its shares. Royalty Pharma plc (NasdaqGS:RPRX) announces a share repurchase program. Under the program, the company will repurchase up to $3,000 million worth of its shares. The shares will be repurchased as part of the company’s evolving approach to returning capital to shareholders. Duyuru • Jan 10
Royalty Pharma plc Declares Dividend for the First Quarter of 2025, Payable on March 10, 2025 Royalty Pharma plc announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2025 to shareholders of record at the close of business on February 21, 2025. Board Change • Jan 08
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Dave Hodgson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Nov 09
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 26% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks High level of debt (64% net debt to equity). Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Upcoming Dividend • Nov 08
Upcoming dividend of US$0.21 per share Eligible shareholders must have bought the stock before 15 November 2024. Payment date: 10 December 2024. Payout ratio is a comfortable 35% but the company is not cash flow positive. Trailing yield: 3.2%. Lower than top quartile of Mexican dividend payers (7.2%). Higher than average of industry peers (2.3%). Reported Earnings • Nov 07
Third quarter 2024 earnings released: EPS: US$0.92 (vs US$0.16 in 3Q 2023) Third quarter 2024 results: EPS: US$0.92 (up from US$0.16 in 3Q 2023). Revenue: US$565.0m (up 5.3% from 3Q 2023). Net income: US$544.0m (up US$471.9m from 3Q 2023). Profit margin: 96% (up from 13% in 3Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Global Pharmaceuticals industry. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Declared Dividend • Oct 21
Second quarter dividend of US$0.21 announced Shareholders will receive a dividend of US$0.21. Ex-date: 15th November 2024 Payment date: 10th December 2024 Dividend yield will be 2.0%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (55% earnings payout ratio) but not covered by cash flows (124% cash payout ratio). The dividend has increased by an average of 8.8% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 43% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Oct 17
Royalty Pharma plc to Report Q3, 2024 Results on Nov 06, 2024 Royalty Pharma plc announced that they will report Q3, 2024 results Pre-Market on Nov 06, 2024 Board Change • Oct 17
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Dave Hodgson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Oct 11
Royalty Pharma Declares Fourth Quarter 2024 Dividend, Payable on December 10, 2024 Royalty Pharma plc has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on December 10, 2024, to shareholders of record at the close of business on November 15, 2024. Board Change • Sep 13
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Dave Hodgson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 09
Second quarter 2024 earnings released: EPS: US$0.23 (vs US$0.51 in 2Q 2023) Second quarter 2024 results: EPS: US$0.23 (down from US$0.51 in 2Q 2023). Revenue: US$537.3m (flat on 2Q 2023). Net income: US$102.0m (down 55% from 2Q 2023). Profit margin: 19% (down from 42% in 2Q 2023). Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Global Pharmaceuticals industry. Board Change • Jul 30
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Dave Hodgson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Jul 24
Royalty Pharma plc Appoints Molly Sawaya as Executive Vice President, Head of Human Capital Royalty Pharma plc announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm’s Human Resources (HR) agenda, including onboarding, colleague engagement, professional development, compensation and benefits. Previously, Molly held a number of global HR roles of increasing responsibility at QBE Insurance Group, Perpetual Limited and National Australia Bank. Molly received her Bachelor of Arts and Master of Applied Science degrees in Psychology from the University of Sydney. Duyuru • Jul 20
Royalty Pharma plc to Report Q2, 2024 Results on Aug 08, 2024 Royalty Pharma plc announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024 Duyuru • Jul 18
Royalty Pharma plc Declares Dividend for the Third Quarter of 2024, Payable on September 13, 2024 Royalty Pharma plc has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the close of business on August 16, 2024. Duyuru • Jun 19
Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director Royalty Pharma plc announced the resignation of Rory Balfour Riggs as director with effect from 6 June 2024. Duyuru • Jun 18
Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director Royalty Pharma plc announced resignation of Mario Germano Giuliani as director with effect from 6 June 2024. Board Change • May 31
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. Independent Director Dave Hodgson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Apr 28
Royalty Pharma plc, Annual General Meeting, Jun 06, 2024 Royalty Pharma plc, Annual General Meeting, Jun 06, 2024, at 09:00 Eastern Daylight. Location: 110 East 59 th Street New York New York United States Agenda: To consider election of each of the eight director nominees listed in the accompanying Proxy Statement by separate ordinary resolutions; to approve on a non-binding advisory basis the compensation of named executive officers; to ratify on a non-binding advisory basis the appointment of Ernst & Young LLP, as independent registered public accounting firm; to approve receipt of our U.K. Annual Report and Accounts for the fiscal year ended December 31, 2023; and to consider other matters. Duyuru • Apr 17
Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024 The board of directors of Royalty Pharma plc has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on June 14, 2024, to shareholders of record at the close of business on May 17, 2024. Board Change • Apr 05
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. Independent Director Dave Hodgson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Apr 04
Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024 Royalty Pharma plc announced that they will report Q1, 2024 results on May 09, 2024 Board Change • Feb 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. Independent Director Dave Hodgson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Feb 07
Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion. Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion on February 5, 2024. Under the agreed transaction, €68 per share will be paid. The agreement is unanimously approved by the Board of Directors of both companies. The transaction is subject to customary closing conditions, including acceptance of the takeover offer by at least 65% of MorphoSys AG’s outstanding shares and receipt of regulatory approvals and is expected to close in the first half of 2024. Centerview Partners is acting as lead financial advisor and Graham Robinson, Faiz Ahmad, Brian V. Breheny, Timothy F. Nelson, Maria Raptis, Resa K. Schlossberg, Jan Bauer, Matthias Horbach, Stephan Hutter and Caspar Schmelzer of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to MorphoSys AG. Jenny Hochenberg, of Freshfields Bruckhaus Deringer US LLP acted as legal advisor to Novartis AG. Duyuru • Jan 31
Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024 Royalty Pharma plc announced that they will report Q4, 2023 results Pre-Market on Feb 15, 2024 Declared Dividend • Jan 29
Third quarter dividend of US$0.21 announced Shareholders will receive a dividend of US$0.21. Ex-date: 15th February 2024 Payment date: 15th March 2024 Dividend yield will be 2.2%, which is lower than the industry average of 2.3%. Sustainability & Growth Dividend is not covered by earnings (191% earnings payout ratio). However, it is well covered by cash flows (35% cash payout ratio). The dividend has increased by an average of 12% per year over the past 3 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 113% to bring the payout ratio under control. EPS is expected to grow by 104% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio. Board Change • Jan 19
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. Independent Director Dave Hodgson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Jan 19
Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024 Royalty Pharma plc announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 15, 2024 to shareholders of record at the close of business on February 16, 2024. Recent Insider Transactions • Jan 01
Director recently sold Mex$120m worth of stock On the 28th of December, Mario Giuliani sold around 252k shares on-market at roughly Mex$476 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth Mex$336m. Insiders have been net sellers, collectively disposing of Mex$499m more than they bought in the last 12 months. Recent Insider Transactions • Dec 18
Director recently sold Mex$336m worth of stock On the 14th of December, Mario Giuliani sold around 672k shares on-market at roughly Mex$500 per share. This transaction amounted to 2.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of Mex$374m more than they bought in the last 12 months. Board Change • Dec 06
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. Independent Director Dave Hodgson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Sep 22
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer Royalty Pharma plc announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenure at Verisk, he led their migration to the cloud, mainframe modernization strategy and Data Governance and Data Strategy Team. Prior to Verisk, Mr. Schneider held senior IT leadership roles at Moody’s Investor Services, Barclay’s Capital, AIG and McKinsey & Company. Board Change • Aug 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. Independent Director Dave Hodgson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Jul 18
Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023 The board of directors of Royalty Pharma plc has approved the payment of a dividend for the third quarter of 2023 of $0.20 per Class A ordinary share. The dividend will be paid on September 15, 2023, to shareholders of record at the close of business on August 18, 2023. Recent Insider Transactions • Jul 17
Executive VP & CFO recently sold Mex$39m worth of stock On the 13th of July, Terrance Coyne sold around 75k shares on-market at roughly Mex$525 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth Mex$113m. This was Terrance's only on-market trade for the last 12 months. Recent Insider Transactions • Jul 06
Founder recently bought Mex$66m worth of stock On the 28th of June, Pablo Legorreta bought around 130k shares on-market at roughly Mex$504 per share. This transaction amounted to 3.6% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth Mex$135m. Pablo has been a buyer over the last 12 months, purchasing a net total of Mex$338m worth in shares. Duyuru • Jun 30
Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023 Royalty Pharma plc announced that they will report Q2, 2023 results on Aug 08, 2023 Recent Insider Transactions • Apr 01
Director recently sold Mex$92m worth of stock On the 30th of March, Rory Riggs sold around 140k shares on-market at roughly Mex$657 per share. This transaction amounted to 8.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of Mex$4.4b more than they bought in the last 12 months. Board Change • Mar 24
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. 1 highly experienced director. Founder, Chairman of the Board & CEO Pablo Legorreta is the most experienced director on the board, commencing their role in 1996. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Upcoming Dividend • Feb 08
Upcoming dividend of US$0.20 per share at 2.1% yield Eligible shareholders must have bought the stock before 15 February 2023. Payment date: 15 March 2023. Payout ratio is a comfortable 64% and the cash payout ratio is 81%. Trailing yield: 2.1%. Lower than top quartile of Mexican dividend payers (5.9%). Lower than average of industry peers (2.4%). Board Change • Jan 31
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. 1 highly experienced director. Founder, Chairman of the Board & CEO Pablo Legorreta is the most experienced director on the board, commencing their role in 1996. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • Jan 16
Royalty Pharma plc to Report Q4, 2022 Results on Feb 15, 2023 Royalty Pharma plc announced that they will report Q4, 2022 results on Feb 15, 2023 Duyuru • Jan 10
Royalty Pharma Declares First Quarter 2023 Dividend, Payable on March 15, 2023 Royalty Pharma plc declared a dividend for the first quarter of 2023 of $0.20 per Class A share, reflecting a 5.3% increase in the company's quarterly dividend over the previous quarter's dividend. The dividend will be paid on March 15, 2023 to shareholders of record at the close of business on February 16, 2023. Recent Insider Transactions • Aug 31
Director recently sold Mex$438k worth of stock On the 25th of August, Mario Giuliani sold around 500 shares on-market at roughly Mex$877 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth Mex$81m. Insiders have been net sellers, collectively disposing of Mex$936m more than they bought in the last 12 months. Board Change • Aug 22
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. 1 highly experienced director. Founder, Chairman of the Board & CEO Pablo Legorreta is the most experienced director on the board, commencing their role in 1996. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Jul 05
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. 1 highly experienced director. Founder, Chairman of the Board & CEO Pablo Legorreta is the most experienced director on the board, commencing their role in 1996. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • Jun 12
Insider recently sold Mex$81m worth of stock On the 8th of June, James Reddoch sold around 100k shares on-market at roughly Mex$814 per share. In the last 3 months, there was an even bigger sale from another insider worth Mex$118m. Insiders have been net sellers, collectively disposing of Mex$870m more than they bought in the last 12 months. Recent Insider Transactions • Jun 02
Insider recently sold Mex$79m worth of stock On the 27th of May, George Lloyd sold around 100k shares on-market at roughly Mex$789 per share. In the last 3 months, there was an even bigger sale from another insider worth Mex$118m. Insiders have been net sellers, collectively disposing of Mex$1.2b more than they bought in the last 12 months. Recent Insider Transactions • May 30
Insider recently sold Mex$80m worth of stock On the 23rd of May, George Lloyd sold around 100k shares on-market at roughly Mex$798 per share. In the last 3 months, there was an even bigger sale from another insider worth Mex$118m. Insiders have been net sellers, collectively disposing of Mex$1.1b more than they bought in the last 12 months. Board Change • May 30
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. 1 highly experienced director. Founder, Chairman of the Board & CEO Pablo Legorreta is the most experienced director on the board, commencing their role in 1996. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • May 25
Director recently sold Mex$118m worth of stock On the 20th of May, Rory Riggs sold around 150k shares on-market at roughly Mex$783 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of Mex$998m more than they bought in the last 12 months. Upcoming Dividend • May 13
Upcoming dividend of US$0.19 per share Eligible shareholders must have bought the stock before 19 May 2022. Payment date: 15 June 2022. Payout ratio is a comfortable 49% but the company is paying out more than the cash it is generating. Trailing yield: 1.9%. Lower than top quartile of Mexican dividend payers (6.0%). Lower than average of industry peers (2.4%). Board Change • May 13
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. 1 highly experienced director. Founder, Chairman of the Board & CEO Pablo Legorreta is the most experienced director on the board, commencing their role in 1996. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 
